PaxMedica Inc. (NASDAQ: PXMD) Shares Corporate Update and Commitment to Advancing Therapies for Neurological Disorders, Prepares for Key Engagements with the FDA
PaxMedica is preparing to submit a New Drug Application to the U.S. Food and Drug Administration later this year for using suramin to treat Human African Trypanosomiasis PaxMedica is currently preparing for an associated and very important Type C meeting with the FDA scheduled for June 27th Type C meetings are designated by the FDA to address specific issues in drug development, such as clinical trial design, data requirements, or other scientific matters not covered by Type A or Type B meetings PaxMedica (NASDAQ: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, recently shared corporate updates regarding its continued…
